Journal of Gastrointestinal Surgery

, Volume 15, Issue 3, pp 444–450 | Cite as

Neoadjuvant Therapy for Rectal Cancer: The Impact of Longer Interval Between Chemoradiation and Surgery

  • Luiz Felipe de Campos-Lobato
  • Daniel P. Geisler
  • Andre da Luz Moreira
  • Luca Stocchi
  • David Dietz
  • Matthew F. Kalady
Original Article

Abstract

Purpose

The aim of this study was to determine the effect of a longer interval between neoadjuvant chemoradiation and surgery on perioperative morbidity and oncologic outcomes.

Methods

A colorectal cancer database was queried for clinical stage II and III rectal cancer patients undergoing neoadjuvant chemoradiation followed by proctectomy between 1997 and 2007. The neoadjuvant regimen consisted of long course external beam radiation and 5-fluorouracil chemotherapy. Patients with inflammatory bowel disease, hereditary cancer, extracolonic malignancy, urgent surgery, or non-validated treatment dates were excluded. Patients were divided into two groups according to the interval between chemoradiation and surgery (<8 and ≥8 weeks). Perioperative complications and oncologic outcomes were compared.

Results

One hundred seventy-seven patients were included. Groups were comparable with respect to demographics, tumor, and treatment characteristics. Perioperative complications were not affected by the interval between chemoradiation and surgery. Patients undergoing surgery ≥8 weeks after chemoradiation experienced a significant improvement in pathologic complete response rate (30.8% vs. 16.5%, p = 0.03) and had decreased 3-year local recurrence rate (1.2% vs. 10.5%, p = 0.04). A Cox regression analysis was performed to assess the compounding effect of a complete pathologic response on oncologic outcome. A longer interval correlated with less local recurrence, although statistical significance was not reached (p = 0.07).

Conclusion

An interval between chemoradiation and surgery ≥8 weeks is safe and is associated with a higher rate of pathologic complete response and decreased local recurrence.

Keywords

Rectal cancer Neoadjuvant therapy Pathologic complete response Prognosis Chemotherapy Radiation Radiotherapy 

References

  1. 1.
    Chan AK, Wong A, Jenken D, et al. Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 2005;61:665–677.PubMedCrossRefGoogle Scholar
  2. 2.
    Bosset JF, Nguyen F, Bosset M, et al. Recent advances in the treatment of localized rectal cancer. Curr Oncol Rep 2008;10:220–224.PubMedCrossRefGoogle Scholar
  3. 3.
    Habr-Gama A, Perez RO, Kiss DR, et al. Preoperative chemoradiation therapy for low rectal cancer. Impact on downstaging and sphincter-saving operations. Hepatogastroenterology 2004;51:1703–1707.PubMedGoogle Scholar
  4. 4.
    Minsky BD, Cohen AM, Kemeny N, et al. Combined modality therapy of rectal cancer: decreased acute toxicity with the preoperative approach. J Clin Oncol 1992;10:1218–1224.PubMedGoogle Scholar
  5. 5.
    Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731–1740.PubMedCrossRefGoogle Scholar
  6. 6.
    Francois Y, Nemoz CJ, Baulieux J, et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol 1999;17:2396.PubMedGoogle Scholar
  7. 7.
    Kalady MF, de Campos-Lobato LF, Stocchi L, et al. Predictive Factors of Pathologic Complete Response After Neoadjuvant Chemoradiation for Rectal Cancer. Ann Surg 2009 (in press).Google Scholar
  8. 8.
    Lavery IC, Lopez-Kostner F, Fazio VW, et al. Chances of cure are not compromised with sphincter-saving procedures for cancer of the lower third of the rectum. Surgery 1997;122:779–784; discussion 784–785.PubMedCrossRefGoogle Scholar
  9. 9.
    Lavery IC, Lopez-Kostner F, Pelley RJ, et al. Treatment of colon and rectal cancer. Surg Clin North Am 2000;80:535–569, ix.PubMedCrossRefGoogle Scholar
  10. 10.
    Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med 1997;336:980–987.Google Scholar
  11. 11.
    Cedermark B, Johansson H, Rutqvist LE, et al. The Stockholm I trial of preoperative short term radiotherapy in operable rectal carcinoma. A prospective randomized trial. Stockholm Colorectal Cancer Study Group. Cancer 1995;75:2269–2275.PubMedCrossRefGoogle Scholar
  12. 12.
    Dahlberg M, Glimelius B, Pahlman L. Improved survival and reduction in local failure rates after preoperative radiotherapy: evidence for the generalizability of the results of Swedish Rectal Cancer Trial. Ann Surg 1999;229:493–497.PubMedCrossRefGoogle Scholar
  13. 13.
    Gerard A, Buyse M, Nordlinger B, et al. Preoperative radiotherapy as adjuvant treatment in rectal cancer. Final results of a randomized study of the European Organization for Research and Treatment of Cancer (EORTC). Ann Surg 1988;208:606–614.PubMedCrossRefGoogle Scholar
  14. 14.
    Mohiuddin M, Winter K, Mitchell E, et al. Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012. J Clin Oncol 2006;24:650–655.PubMedCrossRefGoogle Scholar
  15. 15.
    Chau I, Brown G, Cunningham D, et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol 2006;24:668–674.PubMedCrossRefGoogle Scholar
  16. 16.
    Lawson JD, Kauh J, Koshy M, et al. Early clinical results from chemoradiation with 5-fluorouracil and oxaliplatin for locally advanced rectal cancer. Clin Colorectal Cancer 2008;7:325–330.PubMedCrossRefGoogle Scholar
  17. 17.
    Carlomagno C, Farella A, Bucci L, et al. Neo-adjuvant treatment of rectal cancer with capecitabine and oxaliplatin in combination with radiotherapy: a phase II study. Ann Oncol 2009;20:906–912.PubMedCrossRefGoogle Scholar
  18. 18.
    Rosenthal DI, Catalano PJ, Haller DG, et al. Phase I study of preoperative radiation therapy with concurrent infusional 5-fluorouracil and oxaliplatin followed by surgery and postoperative 5-fluorouracil plus leucovorin for T3/T4 rectal adenocarcinoma: ECOG E1297. Int J Radiat Oncol Biol Phys 2008;72:108–113.PubMedCrossRefGoogle Scholar
  19. 19.
    Tran CL, Udani S, Holt A, et al. Evaluation of safety of increased time interval between chemoradiation and resection for rectal cancer. Am J Surg 2006;192:873–877.PubMedCrossRefGoogle Scholar
  20. 20.
    Moore HG, Gittleman AE, Minsky BD, et al. Rate of pathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer resection. Dis Colon Rectum 2004;47:279–286.PubMedCrossRefGoogle Scholar
  21. 21.
    Stein DE, Mahmoud NN, Anne PR, et al. Longer time interval between completion of neoadjuvant chemoradiation and surgical resection does not improve downstaging of rectal carcinoma. Dis Colon Rectum 2003;46:448–453.PubMedCrossRefGoogle Scholar
  22. 22.
    Tulchinsky H, Shmueli E, Figer A, et al. An interval >7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer. Ann Surg Oncol 2008;15:2661–2667.PubMedCrossRefGoogle Scholar
  23. 23.
    Habr-Gama A, Perez RO, Proscurshim I, et al. Interval between surgery and neoadjuvant chemoradiation therapy for distal rectal cancer: does delayed surgery have an impact on outcome? Int J Radiat Oncol Biol Phys 2008;71:1181–1188.PubMedCrossRefGoogle Scholar
  24. 24.
    Messick CA, Sanchez J, Dejulius KL, et al. Genetic and molecular diversity of colon cancer hepatic metastases. Surgery 2009;146:227–231.PubMedCrossRefGoogle Scholar
  25. 25.
    Watanabe T. Chemoradiotherapy and adjuvant chemotherapy for rectal cancer. Int J Clin Oncol 2008;13:488–497.PubMedCrossRefGoogle Scholar
  26. 26.
    Wolmark N, Rockette H, Fisher B, et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 1993;11:1879–1887.PubMedGoogle Scholar

Copyright information

© The Society for Surgery of the Alimentary Tract 2010

Authors and Affiliations

  • Luiz Felipe de Campos-Lobato
    • 1
  • Daniel P. Geisler
    • 1
  • Andre da Luz Moreira
    • 1
    • 2
  • Luca Stocchi
    • 1
  • David Dietz
    • 1
  • Matthew F. Kalady
    • 1
  1. 1.Department of Colorectal SurgeryDigestive Disease Institute, Cleveland ClinicClevelandUSA
  2. 2.Department of ColoproctologyUniversity of Rio de JaneiroRio de JaneiroBrazil

Personalised recommendations